View Post

What to Expect When You Have Radiation Treatment

In In The News by Barbara Jacoby

By: Tampa Bay Radiation Oncology Radiation is often a treatment option for cancer. While the procedure itself is usually painless, that doesn’t mean that you won’t feel anxious or overwhelmed—or even scared. Those feelings are perfectly understandable, and you should know that you’re not alone in feeling this way. Knowing what to expect from radiation treatment will help you feel more prepared …

View Post

Cancer researchers find more effective way to deliver promising breast cancer treatment

In In The News by Barbara Jacoby

By: Adrianna MacPherson, University of Alberta From: medicalxpress.com A cancer researcher at the University of Alberta and his team are breathing new life into a promising cancer therapy by improving how the treatment is delivered. Hasan Uludag, a professor in chemical and materials engineering, and his team have developed a chemical compound that allows them to effectively inject genetic material …

View Post

What You Need to Know About the FDA’s Approval of Tukysa for HER2-Positive Breast Cancer

In In The News by Barbara Jacoby

By: Beth Fand Incollingo and Kristi Rosa From: curetoday.com By approving Tukysa (tucatinib) for use with the targeted drug Herceptin (trastuzumab) and the chemotherapy Xeloda (capecitabine), the Food and Drug Administration has provided a meaningful option to heavily pretreated patients with inoperable, locally advanced or metastatic HER2-positive breast cancer, including those with brain metastases, according to Dr. Rashmi Murthy. This …

View Post

Hormone Levels Tied to Future Breast Cancer Risk

In In The News by Barbara Jacoby

By: Kristen Monaco From: medpagetoday.com Circulating progesterone levels may help predict future breast cancer incidence in older women, researchers reported. During a 12-year follow-up period, postmenopausal women saw a modest 16% higher risk for breast cancer with each standard deviation increase in progesterone levels (hazard 1.16, 95% CI 1.00-1.35, P=0.048), Britton Trabert, PhD, MS, of the National Cancer Institute in …

View Post

Generex Subsidiary NuGenerex Immuno-Oncology Announces Publication of Positive Results of the AE37 Phase IIb Breast Cancer Trial

In Clinical Studies News by Barbara Jacoby

Source: Generex Biotechnology Corporation From: globenewswire.com Prospective, randomized, single‑blinded, multi‑center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence Conclusion: AE37 Ii-Key peptide vaccine is safe and associated with DFS in sub-sets of breast cancer survivors after 10-year follow-up In patients with both advanced stage and HER2 under-expression (HER2 2+, 1+, …

View Post

Poor Endocrine Therapy Response in Primary Breast Cancer Possibly Explained by Rare ESR1 Mutations

In In The News by Barbara Jacoby

By: Andrea Anderson From: precisiononcologynews.com Mutations in the estrogen receptor alpha-coding gene ESR1 appear to occur in a small subset of primary breast cancer tumors, potentially providing a window into cases with poorer-than-usual responses to adjuvant, endocrine-based treatments. Several prior studies suggest activating mutations in ESR1 can contribute to treatment resistance in metastatic breast cancer cases, explained Malin Dahlgren, a …

View Post

New fast-track breast cancer treatment takes just FIVE DAYS instead of the standard three weeks

In Clinical Studies News by Barbara Jacoby

By: Ben Spencer From: dailymail.co.uk An NHS trial reveals a five-day course of radiotherapy is as good as three weeks  The high-dosage is proven to be as safe as the standard breast cancer treatment  Hospitals are using the fast-track regime as it reduces coronavirus exposure   Here’s how to help people impacted by Covid-19 Nearly 35,000 breast cancer patients a year …

View Post

New type of immune cell discovered in breast ducts

In In The News by Barbara Jacoby

Source: Walter and Eliza Hall Institute From: eurekalert.org Melbourne breast cancer researchers have discovered a new type of immune cell that helps to keep breast tissue healthy by regulating a vital process within mammary ducts – the sites where milk is produced and transported, but also where most breast cancers arise. Using advanced three-dimensional (3D) imaging techniques, the team observed …

View Post

Durvalumab regimen improves pathologic complete response in HER2-negative breast cancer

In Clinical Studies News by Barbara Jacoby

From: healio.com Durvalumab and olaparib in combination with paclitaxel significantly improved pathologic complete response compared with chemotherapy alone among women with stage II or stage III high-risk, HER2-negative breast cancer, according to results of the randomized phase 2 I-SPY 2 study presented at the virtual American Association for Cancer Research Annual Meeting. Researchers observed improvement among subsets of women with …